EssilorLuxottica Upbeat on Mid-Term Targets Despite Slowing Growth
By Joshua Kirby
EssilorLuxottica's revenue growth slowed in the third quarter amid sluggish sales of sunglasses, but the company backed its longer-term financial targets.
The Franco-Italian eyewear giant made total revenue of 6.29 billion euros ($6.63 billion) in the July-September period, 5.2% higher than in the same period last year, adjusted for currency effects. This was in line with analysts' expectations, according to a poll of estimates compiled by FactSet, but slightly slower than in the first half of the year.
Revenue grew most slowly in the group's largest market, North America, where sales of sunglasses continue to drag overall performance. Sales at retailer Sunglass Hut remained lower on year in the region over the quarter, EssilorLuxottica said.
Weakness in sunglass retail also hit the Europe, Middle East and Africa region, the company said, pointing to unfavorable weather in July and August. In Asia-Pacific, however, revenue rose by double digits, despite a tough comparison base after a strong quarter last year.
Looking ahead, the Ray-Ban maker said it remains confident of netting annual revenue growth in the mid-single digits between 2022 and 2026, as well as reaching an adjusted operating margin of 19%-20%.
"We are doubling down on our strengths," said Francesco Milleri and Paul du Saillant, EssilorLuxottica's chief executive and deputy CEO, respectively, in a joint statement. They pointed to a new joint frame-and-lens factory in Thailand as an example of the group's growing global footprint.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
October 19, 2023 12:46 ET (16:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks